|1.||Perez, Sonia A: 4 articles (11/2014 - 07/2010)|
|2.||Baxevanis, Constantin N: 4 articles (11/2014 - 07/2010)|
|3.||Papamichail, Michael: 3 articles (11/2014 - 07/2010)|
|4.||Anastasopoulou, Eleftheria A: 2 articles (11/2014 - 10/2013)|
|5.||Ponniah, Sathibalan: 2 articles (11/2010 - 07/2008)|
|6.||Benavides, Linda C: 2 articles (11/2010 - 07/2008)|
|7.||Holmes, Jarrod P: 2 articles (11/2010 - 07/2008)|
|8.||Peoples, George E: 2 articles (11/2010 - 07/2008)|
|9.||Gates, Jeremy D: 2 articles (11/2010 - 07/2008)|
|10.||Hueman, Matthew T: 2 articles (11/2010 - 07/2008)|
|1.||Breast Neoplasms (Breast Cancer)
11/03/2010 - "We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for T(Reg) cells and correlated their levels with vaccine-specific immune responses. "
07/10/2008 - "We present the results of the first human phase I trial of the Ii-Key hybrid HER-2/neu peptide (AE37) vaccine in disease-free, node-negative breast cancer patients. "
|2.||Prostatic Neoplasms (Prostate Cancer)
10/01/2013 - "In our recent phase I trial, we demonstrated that the AE37 vaccine is safe and induces HER-2/neu-specific immunity in a heterogeneous population of HER-2/neu (+) prostate cancer patients. "
01/01/2014 - "This commentary is based on a retrospective analysis we performed of data from prostate cancer patients vaccinated and boosted with the AE37 vaccine. "
07/01/2010 - "AE37 vaccine is safe and can induce HER-2/neu-specific cellular immune responses in patients with castrate-sensitive and castrate-resistant prostate cancer, thus emphasizing the potential of AE37 to target HER-2/neu for the immunotherapy of prostate cancer."
11/01/2014 - "We found that preexisting levels of transforming growth factor beta (TGF-β) had an inverse correlation with in vivo and in vitro immunologic responses to the AE37 vaccine which were measured as delayed-type hypersensitivity (DTH) and interferon gamma (IFN-γ) production in response to the native HER-2(776-790) (or AE36) peptide, respectively. "
|1.||invariant chain (Ii-Key)
|2.||Transforming Growth Factor beta (TGF-beta)
|3.||Interferon-gamma (Interferon, gamma)